SEARCH

SEARCH BY CITATION

References

  • 1
    von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N. American Cancer Society guideline for the early detection of prostate cancer: update 1997. CA Cancer J Clin 1997; 47: 261264
  • 2
    Hautzel H, Muller-Mattheis V, Herzog H et al. The (11C) acetate positron emission tomography in prostatic carcinoma. New prospects in metabolic imaging. Urologe A 2002; 41: 569576
  • 3
    Dimitrakopoulou-Strauss A, Strauss LG. PET imaging of prostate cancer with 11C-acetate. J Nucl Med 2003; 44: 556558
  • 4
    Caroli P, Nanni C, Rubello D, Alavi A, Fanti S. Non-FDG PET in the practice of oncology. Indian J Cancer 2010; 47: 120125
  • 5
    Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol) 2010; 22: 4655
  • 6
    Sadeghi R, Gholami H, Zakavi SR, Kakhki VR, Horenblas S. Accuracy of 18F-FDG PET/CT for diagnosing inguinal lymph node involvement in penile squamous cell carcinoma: systematic review and meta-analysis of the literature. Clin Nucl Med 2012; 37: 436441
  • 7
    Grassi I, Nanni C, Allegri V et al. The clinical use of PET with 11C-acetate. Am J Nucl Med Mol Imaging 2012; 2: 3347
  • 8
    OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine. Available at: http://www.cebm.net/index.aspx?o=5653. Accessed June 2013
  • 9
    Devillé WL, Buntinx F, Bouter LM et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002; 2: 9
  • 10
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177188
  • 11
    Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993; 12: 12931316
  • 12
    Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002; 21: 12371256
  • 13
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629634
  • 14
    Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455463
  • 15
    Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31
  • 16
    Oyama N, Akino H, Kanamaru H et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43: 181186
  • 17
    Kato T, Tsukamoto E, Kuge Y et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002; 29: 14921495
  • 18
    Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2002; 29: 13801384
  • 19
    Oyama N, Miller TR, Dehdashti F et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44: 549555
  • 20
    Fricke E, Machtens S, Hofmann M et al. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003; 30: 607611
  • 21
    Kotzerke J, Volkmer BG, Glatting G et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42: 2530
  • 22
    Alavi S, Kurtaran A, Ilruby S, Wachter S, Malberger M, Djavan B. Multicenter evaluation of carbon-II acetate pet imaging in men with PSA progression following radical prostatectomy. Eur Urol Supp 2003; 2: 22
  • 23
    de Jong IJ, Pruim J, Jongen MMGJ, Elsinga PH, Mensink HJA, Vaalburg W. Visualization and quantification of uptake of 11C-acetate in prostate cancer and in benign prostatic hyperplasia with PET. Groningen University, The Netherlands, Thesis. 2003
  • 24
    Seltzer MA, Jahan SA, Dahlbom M et al. Combined metabolic imaging using C-11 acetate and FDG PET for the evaluation of patients with suspected recurrent prostate cancer. J Nucl Med 2003; 44: 132P
  • 25
    Manente P, Vicario G, Chierichetti F, Liessi G, Bissoli S. Preliminary experience with 11C-acetate and positron emission tomography (PET) in prostate cancer. J Clin Oncol 2005; 23: 422S
  • 26
    Albrecht S, Buchegger F, Soloviev D et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007; 34: 185196
  • 27
    Vees H, Buchegger F, Albrecht S et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 2007; 99: 14151420
  • 28
    Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 2006; 67: 9961000
  • 29
    Wachter S, Tomek S, Kurtaran A et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006; 24: 25132519
  • 30
    Schumacher D, Sorensen J, Brekkan E, Wassberg C, Malmstrom PU. The value of 11C-Acetate PET for lymph node staging in patients with newly diagnosed prostate cancer – results of a prospective study. Eur Urol Suppl 2009; 8: 319
  • 31
    Han KS, Cho KS, Joung JY et al. Localization of prostate cancer: a prospective intra-patient comparison study of MR imaging, fluorine 18-fluorodeoxyglucose PET/CT and carbon 11-Acetate PET/CT. Eur Urol Suppl 2009; 8: 355
  • 32
    Arenas JL, Canby-Hagino E. The efficacy of 11 carbon acetate PET scan in the staging and management of prostate cancer. J Urol 2009; 181: 781
  • 33
    Vees H, Buchegger F, Khan HG et al. Multiple Frame 18F-Fluorocholine or 11C-Acetate PET/CT Compared with Multi-modality MRI in Prostate Cancer Patients after Curative RT without Evidence of Relapse. Int J Rad Oncol Biol Physics 2009; 75: S349350
  • 34
    Oyama N, Tanase K, Ito H et al. 11C-acetate PET imaging of recurrent prostate cancer after radical prostatectomy detection of recurrent disease under PSA of 3.0 ng/mL. J Urol 2010; 183: e792
  • 35
    Yu EY, Muzi M, Hackenbracht JA et al. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 2011; 36: 192198
  • 36
    Müller-Mattheis V, Fahlbusch M, Hautzel H, Albers P. 11C-Acetate PET/CT imaging of prostate cancer: detection of recurrent disease in patients with PSA relapse following radical prostatectomy or radiotherapy. Eur Urol Suppl 2011; 10: 302
  • 37
    Jambor I, Borra R, Kemppainen J et al. Improved detection of localized prostate cancer using co-registered MRI and (11)C-acetate PET/CT. Eur J Radiol 2012; 81: 29662972
  • 38
    Mena E, Turkbey B, Mani H et al. 11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med 2012; 53: 538545
  • 39
    Haseebuddin M, Dehdashti F, Siegel BA et al. 11C-Acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med 2013; 54: 699706
  • 40
    Sadeghi R, Tabasi KT, Bazaz SM et al. Sentinel node mapping in the prostate cancer. Meta-analysis. Nuklearmedizin 2011; 50: 107115
  • 41
    Picchio M, Briganti A, Fanti S et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011; 59: 5160
  • 42
    Buchegger F, Garibotto V, Zilli T et al. First results of a comparative, prospective 11C-acetate and 18F-fluorocholine PET/CT study in prostate cancer patients relapsing after curative treatment with low PSA. Eur J Nucl Med Mol Imaging 2012; 39: S396
  • 43
    Fanti S, Nanni C, Lopci E et al. Imaging with (11)Carbon labelled PET tracers. Nucl Med Commun 2010; 31: 613616
  • 44
    Gomez JH, Blake M, Hernandez JO, Balam J, Teh BS. C11-Acetate positron emission tomography (PET) for prostate cancer patients undergoing radiation therapy. Int J Radiat Oncol Biol Phys 2012; 84: 371372
  • 45
    Morris MJ, Scher HI. (11)C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34: 181184